Bioventus to Provide CVS Caremark® with its Portfolio of Preferred Options for Knee Osteoarthritis Patients Seeking Pain Relief

All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, November 10, 2020
Information
Tags: 
Managed care, Biotechnology, Pharmaceutical, Health, Nervous system, Acute pain, Branches of biology, Health sciences, Woonsocket, Rhode Island, Palliative care, Pain management, CVS, Pain, Formulary, CVS Health
Geotags: 
United States, North Carolina
⚠ generated by AI ↴
Organisation: 
BIOVENTUS
Summary
Key Points: 
  • All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.
  • CVS Caremark members now have access to the broadest HA portfolio available to patients and physicians in the US, said John Nosenzo, Chief Commercial Officer, Bioventus.
  • DUROLANE, GELSYN-3 and SUPARTZ FX, all from Bioventus, provide long lasting OA knee pain relief allowing patients to resume more active lives.
  • Risks can include general knee pain, warmth and redness or pain at the injection site.


Beginning January 1, 2021 Bioventus, a global leader in Innovations For Active Healing, will gain preferred access through the CVS Caremark Formulary, to DUROLANE®, GELSYN-3® and SUPARTZ FX®, for the treatment of knee osteoarthritis (OA) pain. CVS Caremark manages the drug benefits for more than 40 million lives, which includes the prescription drug benefits of 6 million Aetna members.

DUROLANE, is a single-injection, GELSYN-3, a three-injection, and SUPARTZ FX, a five-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.

“CVS Caremark members now have access to the broadest HA portfolio available to patients and physicians in the US,” said John Nosenzo, Chief Commercial Officer, Bioventus. “DUROLANE, GELSYN-3 and SUPARTZ FX, all from Bioventus, provide long lasting OA knee pain relief allowing patients to resume more active lives.”

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.

More information about the entire Bioventus portfolio of HA-based products is found at www.OAKneePainRelief.com.

Bioventus, the Bioventus logo, GELSYN-3 and DUROLANE are registered trademarks of Bioventus LLC. SUPARTZ FX is a registered trademark of Seikagaku Corp. CVS Caremark is a registered trademark of CVS Pharmacy, Inc.

Summary of Indications for Use:

DUROLANE is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in package insert, at www.DUROLANE.com, or by contacting Bioventus Customer Service at 1-800-836-4080.

GELSYN-3 is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g. acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site. GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found in product labeling, at www.GELSYN3.com or by contacting customer service at 1-800-836-4080.

SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to avian (bird) products (feathers and eggs). SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found in product labeling, at www.SupartzFX.com or by contacting customer service at 1-800-836-4080.

Copyright: 
Copyright Business Wire 2020